Choline alphoscerate, 250 mg/ml 4 ml 3 pcs.

Choline alphocerate as a carrier of choline and precursor of phosphatidylcholine has the potential ability to prevent and correct biochemical damage, which are of particular importance among the pathogenetic factors of psychoorganic involutional syndrome, that is, can influence the reduction of cholinergic transmission and damaged phospholipid composition of nerve cell membranes.

The chemical structure of choline alphoscerate (containing 40.5% choline) has the property of metabolic protection and ensures the release of the active substance – choline in the brain tissues.

Choline alphocerate has a positive effect on memory functions and cognitive abilities, as well as indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional brain pathology.

Pharmacokinetics

The pharmacokinetic characteristics of the radioactively labeled drug were similar in different animal species (rats, dogs, monkeys) and were as follows absorption from the gastrointestinal tract is complete and rapid; it rapidly accumulates and distributes to various organs and tissues, including the brain; renal excretion is about 10% of the administered dose in 96 hours; and drug concentration is higher in the brain compared to tritium-labeled choline.

Indications

Psychoorganic syndrome against the background of involutional and degenerative processes in the brain, the consequences of cerebrovascular insufficiency or primary and secondary cognitive impairment in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased concentration.

Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest.

Senile pseudomelancholia.

Pharmacological effect

Choline alphoscerate, as a carrier of choline and a precursor of phosphatidylcholine, has the potential ability to prevent and correct biochemical damage, which is of particular importance among the pathogenetic factors of psychoorganic involution syndrome, that is, it can affect the reduction of cholinergic transmission and damaged phospholipid composition of nerve cell membranes.

The chemical structure of choline alfoscerate (containing 40.5% choline) has the property of metabolic protection and ensures the release of the active substance – choline in brain tissue.

Choline alfoscerate has a positive effect on memory functions and cognitive abilities, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional pathology of the brain.

Pharmacokinetics

The pharmacokinetic characteristics of the radiolabeled drug were similar in different animal species (rats, dogs, monkeys) and were as follows: absorption from the gastrointestinal tract is complete and rapid; quickly accumulates and distributes in various organs and tissues, including the brain; renal excretion is approximately 10% of the administered dose in 96 hours; the concentration of the drug is higher in the brain compared to tritium-labeled choline.

Special instructions

Nausea may result from dopaminergic activation.

Active ingredient

Choline alphoscerate

Composition

Active substance:

Contraindications

Hypersensitivity to choline alfoscerate and drugs with a similar chemical structure;
Hemorrhagic stroke (acute stage);
Pregnancy;
Lactation period;
Children under 18 years of age.

Side Effects

From the digestive system: constipation, diarrhea, nausea, dry oral mucosa, pharyngitis.

From the nervous system: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, dizziness.

From the skin: rash, urticaria.

Other: pain at the injection site, increased urination.

Interaction

No significant drug interactions between choline alfoscerate and other drugs have been identified.

Overdose

Symptoms: nausea.

Manufacturer

Ellara LLC, Russia